Core Viewpoint - The article highlights the participation of DaoSheng Biotechnology (Shenzhen) Co., Ltd. in the 2026 DT New Leaf Award, specifically competing for the "Innovative Materials Award" with its synthetic biological pigment, synthetic indigo [3][12]. Group 1: Company Overview - DaoSheng Biotechnology was established in October 2022 and is the world's first company to achieve large-scale production of synthetic biological indigo pigment [4]. - The company offers integrated solutions for synthetic biological pigments, including indigo, indigo red, and melanin, aiming to promote the transformation of traditional industries towards safety, environmental protection, and sustainability [4]. Group 2: Product Participation - The synthetic biological indigo is positioned as a solution to the high pollution associated with traditional dyeing industries, leveraging synthetic biology technology to transition from "traditional chemical synthesis" to "green biological manufacturing" [5]. - The synthetic indigo boasts several advantages: - High purity: Indigo purity is ≥40%, with customization options available [9]. - Pollution-free: The product contains no harmful substances like aniline or formaldehyde, making it suitable for cosmetics, biomedicine, and food additives [5][9]. - Strong color fastness: Color fastness reaches levels 4-5, allowing it to directly replace traditional chemical indigo without additional costs [9]. - Multifunctional: Retains the antibacterial, deodorizing, and UV protection properties of natural indigo [9][11]. Group 3: Market Position and Achievements - DaoSheng Biotechnology focuses on the synthetic biological natural pigment sector, which combines "natural health attributes" with "industrial scalability," meeting both consumer demand for safe and sustainable products and industry needs for large-scale production [6]. - The company has completed several million yuan in financing, holds multiple core invention patents, and has established an 8-ton demonstration production line to support market supply [6]. - The indigo products have received ISO9001, ISO14001, and ISO45001 certifications, as well as USDA bio-based certification and FDA registration, positioning the company favorably for government procurement in North America [6].

Core Viewpoint - The chairman and actual controller of Dabeinong, Shao Genhuo, passed away on February 3, 2026, at the age of 60, but the company's operations continue normally [1][2]. Group 1: Company Leadership and Operations - The board of directors and senior management are functioning normally, and all business operations are ongoing without disruption [2]. - Following Shao Genhuo's death, the number of directors in the company decreased from 9 to 8, which does not violate the legal minimum for board members [4]. Group 2: Background of Shao Genhuo - Shao Genhuo was born in 1965, a member of the Communist Party, and held a PhD in agronomy from China Agricultural University. He founded Beijing Dabeinong Technology Group Co., Ltd. in October 1994 [3]. - He emphasized innovation as the core of the company, which has a research team of 2,000 and has established a national key laboratory [3]. Group 3: Recent Company Activities - Dabeinong held the 2025 Academic Annual Meeting and the First Green Bio-Manufacturing Young Scientists Forum in January 2026, which Shao Genhuo attended [3]. - The company announced a share reduction plan executed by Shao Genhuo, where he sold a total of 49,445,195 shares, representing 1.15% of the total share capital [4].

Core Viewpoint - The article highlights the launch of a significant industrial project by Bojiao Biotechnology, focusing on synthetic biology and green manufacturing, with a total investment of 1.275 billion yuan, aiming for production capacity and substantial annual sales revenue [1][3]. Group 1: Project Overview - Bojiao Biotechnology's industrialization and research project is a provincial key industrial initiative with a total investment of 1.275 billion yuan [1]. - The project is expected to complete its core production and supporting facilities from January 2026 to June 2027, with production capacity reaching 156.2 tons of raw materials, 300 million dosage forms, and 15 million bottles annually [1]. - The anticipated annual sales revenue is projected to exceed 5 billion yuan, with annual tax and profit exceeding 500 million yuan [1]. Group 2: Technological Focus - The project is centered around synthetic biology, integrating AI smart manufacturing and green manufacturing concepts, establishing a comprehensive technical system from strain construction to structural modification [1]. - Bojiao Biotechnology has developed four major technology platforms, including molecular biology, enzyme engineering, green chemistry, and drug delivery, positioning itself in the core technology of terpenoid pharmaceuticals [4]. - The company collaborates closely with Jay Keasling, a pioneer in synthetic biology, and his company Demetrix, aiming to develop more efficient and sustainable biosynthetic processes [5].

Core Insights - The company, Baiyin Biotechnology, focuses on the development of innovative biomaterials, leveraging high-throughput synthetic biology and artificial intelligence to create sustainable and low-cost solutions in the biomaterials sector [1] Group 1: Company Overview - Baiyin Biotechnology has successfully launched several core products, including recombinant mussel adhesive protein, Colamin sodium alginate, and fibronectin, gaining recognition from multiple Fortune 500 companies [1] - The company has completed nearly 300 million yuan in financing, with investments from notable institutions such as Wu Bo Lian Guang Pharmaceutical Fund and Wuyuan Capital, providing solid support for technological research and industrialization [1] Group 2: Product Innovation - The recombinant mussel adhesive protein, known as "marine soft gold," has significant value in wound care and medical aesthetics, but traditional production methods face challenges such as low yield and high resource consumption [2] - Baiyin Biotechnology has developed a green biomanufacturing system for recombinant mussel adhesive protein using synthetic biology, achieving the highest yield strains globally, which can replace billions of mussels in extraction [2] - The company has addressed application challenges such as compatibility and discoloration, creating multi-scenario solutions and establishing a robust intellectual property system to ensure product safety and stability [2] Group 3: Industry Impact - The project has established Baiyin Biotechnology as the first company in China to complete the medical device raw material filing for recombinant mussel adhesive protein and to lead the formulation of the first related group standard, filling a gap in the industry [2] - By March 2025, the company is expected to receive multiple medical device product registrations centered on recombinant mussel adhesive protein, launching a comprehensive series of products for wound care and mucosal repair [2] - The project transforms the traditional model reliant on natural resource extraction, setting a benchmark for "green alternatives to traditional methods," significantly reducing production costs and promoting the accessibility of high-performance biomaterials [2][3]

Core Viewpoint - The article highlights a significant breakthrough in the biosynthesis of medium-chain fatty acids (MCFAs) by a research team led by Professor Wang Dan from Chongqing University, utilizing engineered Escherichia coli and bamboo waste as a substrate, achieving a production yield of 9.05 g/L in a 5 L fermentation tank [2][5]. Group 1: Research Breakthroughs - The research team constructed an efficient synthesis pathway in E. coli by deleting specific genes to block β-oxidation and enhance the utilization of multiple carbon sources, resulting in an initial MCFA yield of 2.29 g/L [4]. - Further enhancements were made using protein engineering techniques, achieving a yield of 5.83 g/L and the first synthesis of C6 fatty acids [4]. - The introduction of a carbonic anhydrase gene from Anabaena sp. 7120 improved CO₂ conversion efficiency, raising the yield to 6.72 g/L, and subsequent overexpression of a fatty acid regulatory factor led to a final yield of 9.05 g/L [5]. Group 2: Economic and Environmental Impact - The economic analysis indicates that using bamboo waste hydrolysate instead of glucose as a carbon source reduces the production cost of MCFAs by approximately 17% per ton, showcasing both economic and environmental advantages of this biosynthetic route [5]. Group 3: Institutional Background - Chongqing University is a key national research university, actively contributing to regional and industrial development, with significant achievements in research funding and project approvals [7][8]. - The university's chemical engineering and technology programs rank highly globally, reflecting its strong academic capabilities and commitment to innovation in fields like bio-manufacturing [8]. Group 4: Research Team and Leadership - Professor Wang Dan leads the research team, focusing on biosynthesis of chemical products and new materials, with numerous publications in high-impact journals and significant contributions to national research projects [9].

Core Viewpoint - Weihe Biotechnology has completed a seed round of financing, led by QuanHua Life, focusing on life sciences investment [1] Group 1: Financing Details - The funds raised will primarily be used for the development of a research platform, building a research team, and pilot production of core products [1] - The financing aims to accelerate the biomanufacturing of high-value food new materials, providing more sustainable solutions for the health industry [1] Group 2: Company Focus and Goals - Weihe Biotechnology officially established its presence in the Beijing Agricultural Zhongguancun Science Park in October 2025 [1] - The company is focused on constructing and optimizing efficient cell factories, aiming to promote green biomanufacturing of functional proteins and small molecular active substances [1]

Core Viewpoint - The article discusses the advancements in glycosyltransferase engineering for the efficient glycosylation of flavonoids, highlighting the potential applications in health and wellness products, as well as in the fields of agriculture and biomedicine [5][11]. Summary by Sections Glycosylation of Flavonoids - Flavonoids are important plant secondary metabolites with significant biological activities used in disease prevention and treatment [3]. - The glycosylation of flavonoids is catalyzed by plant UDP-glycosyltransferases (UGTs), which is a green and economical method compared to traditional chemical synthesis [3][4]. Research Findings - The study identified a rare glycosyltransferase, UGT75AJ2, capable of catalyzing the glycosylation at C-3' and C-7 hydroxyl positions of flavonoids, leading to the directed synthesis of bioactive flavonoid glycosides [5][6]. - The research demonstrated that glycosylation at these positions enhances antioxidant and blood sugar-lowering activities [4]. Engineering Strategies - A custom FRISM strategy was developed for the rational design of UGTs, resulting in a quadruple mutant (Mut4-1) of UGT75AJ2 with 128 times the catalytic activity of the wild type [7]. - The strategy was also successfully applied to other glycosyltransferases, validating its effectiveness and versatility [7][8]. Implications and Applications - The study provides a new paradigm for enhancing the activity, donor promiscuity, and regioselectivity of plant glycosyltransferases, which is crucial for the biosynthesis of high-value flavonoid glycosides [11]. - This research integrates multiple disciplines, including food science, synthetic biology, artificial intelligence, and pharmacology, contributing to the development of health products with medicinal value [11].

Core Insights - The article discusses the significance of green biomanufacturing in achieving carbon neutrality and sustainable development, highlighting the recognition of key scientists in the field [2][4][5]. Group 1: Green Biomanufacturing Potential - Biomanufacturing is projected to cover 70% of chemical manufacturing products by the end of this century, with an expected economic value of $30 trillion by 2050, although the current industry scale is less than $8 trillion [4][5]. - The concept of third-generation biomanufacturing, which utilizes carbon dioxide as a raw material, is emphasized as a crucial advancement for addressing carbon neutrality [4][5]. Group 2: Challenges and Innovations - Major scientific challenges include efficiently capturing and activating inert carbon dioxide molecules, requiring the design of new enzyme catalysts and light-enzyme coupling systems [5][6]. - Engineering challenges involve scaling up efficient but fragile biological systems to create stable, continuous, and low-cost reactors, transitioning from laboratory to industrial applications [5][6]. Group 3: Interdisciplinary Collaboration - Effective interdisciplinary collaboration is essential, necessitating the establishment of project communities, shared platforms, and talent communities to foster innovation across biology, chemistry, materials, and information fields [6][7]. - Educational reforms are needed to cultivate talent capable of leading the next industrial revolution, focusing on interdisciplinary courses and encouraging exploratory research [6][7]. Group 4: Global Position and Cooperation - China is transitioning from a "follower" to a "leader" in the global green technology race, with advantages in applied research, industrialization, and market scale [7]. - The proposed international cooperation model emphasizes open collaboration in basic research, innovation alliances in key technologies, and self-reliance in core competitive areas [7].

Core Viewpoint - The article emphasizes the significance of green bio-manufacturing as a sustainable development frontier, predicting that by the end of this century, bio-manufactured products could cover 70% of chemical manufacturing products, with bio-manufacturing potentially accounting for one-third of global manufacturing by 2050, creating an economic value of $30 trillion [4][5]. Group 1: Green Bio-Manufacturing Potential - The current scale of the bio-manufacturing industry is less than $8 trillion, indicating substantial growth potential in the future [4]. - The third generation of bio-manufacturing, which utilizes carbon dioxide as a raw material, is expected to significantly contribute to carbon neutrality efforts [5]. Group 2: Key Challenges and Innovations - Major scientific challenges include efficiently capturing and activating inert carbon dioxide molecules, requiring the design of new enzyme catalysts and light-enzyme coupling systems [5]. - Engineering challenges involve scaling up efficient but fragile biological systems to create stable, continuous, and low-cost reactors, transitioning from laboratory to industrial scale [5]. Group 3: Interdisciplinary Collaboration - Achieving deep integration across disciplines such as biology, chemistry, materials science, and information technology requires the establishment of project communities, shared platforms, and talent communities [6]. - Educational reforms are necessary to cultivate interdisciplinary talent capable of leading the next industrial revolution, including curriculum changes and new evaluation methods [6]. Group 4: China's Position in Global Green Technology - China is transitioning from a "follower" to a "leader" in the global green technology race, with advantages in applied research, industrialization, and market scale [7]. - The proposed international cooperation model emphasizes open collaboration in basic research, innovation alliances in key technology areas, and self-reliance in core competitive fields [7].

Group 1 - The core point of the article is that Hangzhou Jingou Biotechnology Co., Ltd. has completed a multi-million A round financing led by Jinding Capital, with participation from several other investment institutions [1] - The financing will primarily be used for research and development investments and the construction of production capacity, aiming to accelerate the large-scale production of high-value-added nutritional health and feed additive products [1] - Jingou Biotechnology, established in 2023, focuses on synthetic biology technology applications in essential areas such as human nutrition and feed additives, with the goal of creating a leading domestic and internationally competitive green biotechnology manufacturing platform [1] Group 2 - The actual controller of Jingou Biotechnology is Wang Zhimin, who holds a total of 55.24% of the shares and serves as the chairman and general manager of the company [3]